Q-omics provides the consensus-scored TSPAN1 profile across patient tissues and cancer cell-line models. TSPAN1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TSPAN1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, TSPAN1 protein abundance shows 18,847 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, COAD, and PDAC as cancer lineages where TSPAN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPAN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPAN1 survival associations across molecular data types. TSPAN1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPAN1 RNA expression–survival associations across cancer types. High TSPAN1 expression shows unfavorable associations in LUAD, GBM and PAAD, but favorable associations in KIRC, SKCM and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TSPAN1 RNA expression.
This table summarizes TSPAN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TSPAN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPAN1 shows lower tumor expression in COAD, KICH, KIRC, THCA and READ and higher tumor expression in BRCA. The COAD box plot shows higher TSPAN1 RNA expression in normal versus tumor tissue (log2 FC = −2.307, t-test p < 0.001).
This table shows molecular features associated with TSPAN1 in patient tissues and cancer cell lines. In patient samples, TSPAN1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPAN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
